TEGA Therapeutics Inc. was founded to exploit glycoscience-related technologies for the treatment of life-threatening diseases. Glycans, or complex carbohydrates, play important roles in many physiological and pathophysiological processes, but their value as pharmaceutical targets remains underexploited by industry. TEGA specializes in the science of glycans. The TEGA pipeline includes two major programs: glycoside-enhanced lysosomal delivery of proteins and recombinant production of heparan sulfate and heparin. The firm aims to improve quality of life for patients by enabling delivery of lifesaving treatments for unmet medical needs. The firm provides insights and rigorous scientific methods to help pharmaceutical companies overcome the obstacle of the blood-brain barrier.
